Superluminal Medicines raised an oversubscribed $60 million Series B to advance a selective, biased MC4R agonist for rare genetic and hypothalamic obesity. The company said it plans to initiate Phase I clinical trials by year-end, with the program focused on energy homeostasis pathways tied to clinically validated MC4R biology. Investors include BVF Partners and participation from Deep Track Capital and Perceptive Advisors, alongside continued support from RA Capital Management, Insight Partners, NVIDIA, and Eli Lilly. Superluminal is using an AI-heavy approach across GPCR targeting and structural biology to design pathway-selective activity intended to reduce side effects. The funding highlights sustained capital demand for differentiated obesity mechanisms beyond incretin modulation, particularly for patient populations with limited therapeutic options.